ELENA BATTISTELLO

Elena Battistello is a key Analyst at Novartis Venture Fund, a leading corporate venture capital firm dedicated to investing in transformative healthcare and life science companies. In her role, Ms. Battistello is instrumental in the fund's investment process, contributing to the sourcing, evaluation, and due diligence of promising early-stage ventures. Her work helps identify companies poised to develop next-generation therapeutics, innovative medical devices, and cutting-edge digital health solutions that align with Novartis' strategic interests and the broader healthcare landscape.

Novartis Venture Fund is known for its commitment to fostering innovation within the biotech and healthcare sectors. As an Analyst, Elena Battistello actively supports the fund's investment thesis by analyzing scientific data, market trends, and competitive landscapes. Her contributions are vital in assessing the scientific merit and commercial viability of potential portfolio companies, ensuring that the fund makes strategic investments that can drive significant impact in patient care. The fund typically focuses on seed to Series B rounds, seeking to partner with entrepreneurs who are developing truly disruptive technologies.

Prior to joining Novartis Venture Fund in 2022, Elena Battistello built a robust foundation in both science and business strategy. She honed her analytical and strategic skills as an Associate at McKinsey & Company, a global management consulting firm, where she advised clients on complex business challenges. This experience provided her with invaluable insights into market dynamics, operational efficiency, and strategic growth, all of which are highly relevant to her current role in venture capital.

Ms. Battistello's deep scientific expertise is rooted in her extensive academic background. She completed a Postdoctoral Fellowship at Harvard Medical School, conducting advanced research that further solidified her understanding of biological systems and medical innovation. Her academic journey also includes earning a PhD in Neuroscience from the prestigious University of Cambridge, following an MSc in Neuroscience from the University of Oxford. She began her scientific studies with a BSc in Biotechnology from the University of Bologna. This comprehensive scientific training equips her with a critical eye for evaluating the scientific rigor and potential of novel biotechnologies and therapeutic platforms.

While specific notable investments directly led by an Analyst like Elena Battistello are typically not publicly disclosed, her involvement is crucial to the success of the fund's overall portfolio. She contributes to the identification and support of companies that are advancing new treatments for various diseases, enhancing diagnostic capabilities, and improving healthcare delivery through digital innovation. Her blend of scientific acumen and strategic business insight makes her a valuable asset to the Novartis Venture Fund team, helping to shape the future of healthcare investment.